MedTrace Logo

Clinical Trial to Evaluate the Regeneration of Articular Cartilage Through Arthroscopy After MegaCarti® Application

NCT06278480 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-10-09

No results posted yet for this study

Summary

The MegaCarti® is the decellularized allogeneic cartilage and acts as a cover after bone marrow stimulation to prevent the loss of blood clots and induces cartilage regeneration by assisting in the location of stem cells derived from bone marrow. During the 48-week confirmatory clinical trial of MegaCarti®, patients who simultaneously underwent high tibial osteotomy(HTO) were treated with a group in which MegaCarti® was implanted after microfracture and a group in which microfracture alone was performed. Cartilage regeneration is evaluated in patients with arthroscopy data at the time of fixation removal surgery.

Conditions

  • Osteoarthritis, Knee

Interventions

DEVICE

MegaCarti®

Medical devices containing allogeneic cartilage

PROCEDURE

microfracture

microfracture

Sponsors & Collaborators

  • L&C Bio

    lead INDUSTRY

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-23
Primary Completion
2024-03-29
Completion
2024-03-29

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06278480 on ClinicalTrials.gov